共查询到20条相似文献,搜索用时 15 毫秒
1.
Laurie Tomlinson Yuri Boriskin Iain McPhee Stephen Holwill Philip Rice 《Nephrology, dialysis, transplantation》2003,18(1):187-189
2.
Robert L Lins Monique M Elseviers Ronny Daelemans 《Nephrology, dialysis, transplantation》2006,21(4):1066-1068
3.
Yann Goueffic Roger Carbajal Marc Burban Gilles Blancho 《Nephrology, dialysis, transplantation》2006,21(8):2315-2317
4.
Intrarenal arterial aneurysms with haematuria in a patient with tuberous sclerosis complex. 总被引:1,自引:0,他引:1
Thomas Künzi Frank Walther Hans-Peter Marti Felix J Frey Bruno Vogt 《Nephrology, dialysis, transplantation》2005,20(10):2268-2270
5.
Tsuguru Hatta Shuji Tanda Tetsuro Kusaba Keiichi Tamagaki Hisako Kameyama Mitsuhiko Okigaki Keiichi Kanda Satoshi Numata Tomoya Inoue Hitoshi Yaku Sanae Harada Kazuo Takeda Susumu Sasaki 《Nephrology, dialysis, transplantation》2005,20(7):1480-1482
6.
Johnson T Samuel Shahedlal Bari Michael J Kumwenda Keith J Taylor Mark W Atkinson Alistair F Douglas 《Nephrology, dialysis, transplantation》2002,17(12):2249-2251
7.
8.
Giorgina Barbara Piccoli Antonella Sargiotto Massimo Gai Giovanni Cacace Elisabetta Mezza Maura Rossetti Francesca Bermond Giorgio Soragna Alberto Jeantet Giacomo Lanfranco Giuseppe Picciotto Giuseppe Paolo Segoloni 《Nephrology, dialysis, transplantation》2004,19(2):498-501
9.
Rituximab Failed to Improve Nephrotic Syndrome in Renal Transplant Patients With Recurrent Focal Segmental Glomerulosclerosis 总被引:2,自引:0,他引:2
Focal segmental glomerulosclerosis (FSGS) recurs in 30% of patients with FSGS receiving a first renal transplant and in over 80% of patients receiving a second transplant after a recurrence. Recurrence often leads to graft failure. The pathogenesis remains unknown and may involve a circulating permeability factor that initiates injury to the glomerular capillary. There are anecdotal reports of pediatric patients with posttransplant lymphoproliferative disorder (PTLD) and recurrent FSGS who have had remission of proteinuria after treatment with rituximab. These observations have prompted speculation that B cells may play a role in the pathogenesis of recurrent FSGS. We report four consecutive adult patients with early recurrent FSGS refractory or dependent on plasmapheresis who received rituximab (total dose 2000–4200 mg). None of the patients treated with rituximab achieved remission in proteinuria, and one patient experienced early graft loss. In these four adult renal transplant patients with recurrent FSGS, rituximab failed to diminish proteinuria. 相似文献
10.
Tobias Schmook Klemens Budde Claas Ulrich Hans-Hellmut Neumayer Lutz Fritsche Eggert Stockfleth 《Nephrology, dialysis, transplantation》2005,20(1):220-222
11.
Preemptive Plasmapheresis and Recurrence of FSGS in High-Risk Renal Transplant Recipients 总被引:2,自引:0,他引:2
R. Y. Gohh A. F. Yango P. E. Morrissey A. P. Monaco A. Gautam M. Sharma E. T. McCarthy V. J. Savin 《American journal of transplantation》2005,5(12):2907-2912
Recurrent focal segmental glomerulosclerosis (FSGS) following transplantation is ascribed to the presence of a circulating FSGS permeability factor (FSPF). Plasmapheresis (PP) can induce remission of proteinuria in recurrent FSGS. This study addressed the efficacy of pre-transplant PP in decreasing the incidence of recurrence in high-risk patients. Ten patients at high-risk for FSGS recurrence because of rapid progression to renal failure (n = 4) or prior transplant recurrence of FSGS (n = 6) underwent a course of 8 PP treatments in the peri-operative period. Recurrences were identified by proteinuria >3 g/day and confirmed by biopsy. Seven patients, including all 4 with first grafts and 3 of 6 with prior recurrence, were free of recurrence at follow-up (238-1258 days). Final serum creatinine in 8 patients with functioning kidneys averaged 1.53 mg/dL. FSGS recurred within 3 months in 3 patients, each of whom had lost prior transplants to recurrent FSGS. Two of these progressed to end-stage renal disease (ESRD) and the third has significant renal dysfunction. Based on inclusion criteria, recurrence rates of 60% were expected if no treatment was given. Therefore, PP may decrease the incidence of recurrent FSGS in high-risk patients. Definitive conclusions regarding optimal management can only be drawn from larger, randomized, controlled studies. 相似文献
12.
Mukesh Khandelwal Brendan B McCormick Ginette Lajoie Joan Sweet Edward Cole Daniel C Cattran 《Nephrology, dialysis, transplantation》2004,19(2):491-494
13.
Jungraithmayr TC Hofer K Cochat P Chernin G Cortina G Fargue S Grimm P Knueppel T Kowarsch A Neuhaus T Pagel P Pfeiffer KP Schäfer F Schönermarck U Seeman T Toenshoff B Weber S Winn MP Zschocke J Zimmerhackl LB 《Journal of the American Society of Nephrology : JASN》2011,22(3):579-585
Steroid-resistant focal segmental glomerulosclerosis (FSGS) often recurs after renal transplantation. In this international survey, we sought to identify genotype-phenotype correlations of recurrent FSGS. We surveyed 83 patients with childhood-onset primary FSGS who received at least one renal allograft and analyzed 53 of these patients for NPHS2 mutations. The mean age at diagnosis was 6.7 years, and the mean age at first renal transplantation was 13 years. FSGS recurred in 30 patients (36%) after a median of 13 days (range, 1.5 to 152 days). Twenty-three patients received a second kidney transplant, and FSGS recurred in 11 (48%) after a median of 16 days (range, 2.7 to 66 days). None of the 11 patients with homozygous or compound heterozygous NPHS2 mutations developed recurrent FSGS compared with 45% of patients without mutations. These data suggest that genetic testing for pathogenic mutations may be important for prognosis and treatment of FSGS both before and after transplantation. 相似文献
14.
Antonietta De Blasio Giuseppe Palmiero Domenico Russo 《Nephrology, dialysis, transplantation》2005,20(12):2839-2841
15.
Vin-Cent Wu Po-Ren Hsueh Wei-Chou Lin Jenq-Wen Huang Hung-Bin Tsai Yung-Ming Chen Kwan-Dun Wu 《Nephrology, dialysis, transplantation》2004,19(12):3180-3182
16.
Nader Bassilios Marc Tassart Aymeric Restoux Jean-Michel Bigot Eric Rondeau Jean-Daniel Sraer 《Nephrology, dialysis, transplantation》2004,19(4):981-983
17.
Intracapillary proliferative glomerulonephritis due to heavy chain deposition disease. 总被引:1,自引:1,他引:0
Anouk C Vedder Jan J Weening Raymond T Krediet 《Nephrology, dialysis, transplantation》2004,19(5):1302-1304
18.
Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure. 总被引:10,自引:0,他引:10
Jo?lle L Nortier Heinz H Schmeiser Marie-Carmen Muniz Martinez Volker M Arlt Catherine Vervaet Christian H Garbar Philippe Daelemans Jean-Louis Vanherweghem 《Nephrology, dialysis, transplantation》2003,18(2):426-428
19.
Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy. 总被引:2,自引:1,他引:1
Cedric Edwards Andrew House Vahakn Shahinian Greg Knoll 《Nephrology, dialysis, transplantation》2002,17(8):1524-1526
20.
Peter Kotanko Eva Gebetsroither Falko Skrabal 《Nephrology, dialysis, transplantation》2002,17(7):1333-1335